Recruiting OBSERVATIONAL NCT06180590

The Efficacy of Vosevi in Treating DAA-experienced Patients

A Prospective Cohort Study: the Efficacy of Vosevi in Treating Direct Antiviral Agent Therapy Failure Patients

Sponsor: The Third Affiliated Hospital of Guangzhou Medical University

Conditions Chronic Hepatitis C Medication Reaction

Interventions Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]

Updated 4 times since 2024 Last updated: Mar 11, 2024 Started: Feb 28, 2023 Primary completion: Feb 28, 2026 Completion: Feb 28, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06180590, this observational or N/A phase trial focuses on Chronic Hepatitis C and Medication Reaction and remains actively recruiting participants. Sponsored by The Third Affiliated Hospital of Guangzhou Medical University, it has been updated 4 times since 2023, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Apr 2024 — Jul 2024 [monthly]

Recruiting
Jan 2024 — Apr 2024 [monthly]

Recruiting

First recorded

Feb 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Third Affiliated Hospital of Guangzhou Medical University

Data source: The Third Affiliated Hospital of Guangzhou Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China